Abstract
Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.
| Original language | English |
|---|---|
| Pages (from-to) | 37-42 |
| Number of pages | 6 |
| Journal | Diabetes and Metabolic Syndrome: Clinical Research and Reviews |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Gliclazide
- Insulin secretion
- Low dose graded glucose infusion test
- Repaglinide
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Internal Medicine
Cite this
The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide. / Yang, Chun Chun; Lin, Jiunn Diann; Kuo, Ko Lin; Wu, Chung Ze; Li, Jer Chuan; Hung, Yi Jen; Wang, Tso Fu; Lee, Chien Hsing; Kuo, Shi Wen; Pei, Dee.
In: Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 1, No. 1, 02.2007, p. 37-42.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The comparison of second phase insulin secretion in patients treated with repaglinide or gliclazide
AU - Yang, Chun Chun
AU - Lin, Jiunn Diann
AU - Kuo, Ko Lin
AU - Wu, Chung Ze
AU - Li, Jer Chuan
AU - Hung, Yi Jen
AU - Wang, Tso Fu
AU - Lee, Chien Hsing
AU - Kuo, Shi Wen
AU - Pei, Dee
PY - 2007/2
Y1 - 2007/2
N2 - Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.
AB - Aims: Sulfonylurea with long half-life such as gliclazide has sustained stimulation on insulin secretion compared to repaglinide which has short half-life for only about 1 h. In this hospital cohort, randomized, cross-over study, we used modified low dose graded glucose infusion test (M-LDGGI) to evaluate second phase insulin secretion after 4 months of treatment with either gliclazide or repaglinide. Methods: Sixteen fresh type 2 diabetes with age of 49.5 ± 2.6 years old and BMI of 25.3 ± 0.9 kg/m2 were included. After titration and maintain dose stage, all cases were randomized to the repaglinide or gliclazide treatment for 4 months. At the end of each treatment period, an M-LDGGI was done. Results: The general linear model repeated measurement was used to evaluate the plasma glucose, insulin and insulin/glucose curve during M-LDGGI. Although the plasma insulin and insulin/glucose ratios were higher at 40 min and 100-120 min, they did not reach statistically significant. The area under curve of the plasma glucose, insulin and insulin/glucose ratio was also used to evaluate the secretory capacity of beta cell. Although the AUC of the ratio of plasma insulin/plasma glucose seems to be more evident than the curves, they are still not significantly different with each other. Conclusions: In conclusion, although non-significant, better second phase insulin secretion could be noted with treatment of repaglinide than gliclazide for 4 months. Further study with longer duration and larger study cohort are needed to solve this interesting and important question.
KW - Gliclazide
KW - Insulin secretion
KW - Low dose graded glucose infusion test
KW - Repaglinide
UR - http://www.scopus.com/inward/record.url?scp=34247846308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247846308&partnerID=8YFLogxK
U2 - 10.1016/j.dsx.2006.11.006
DO - 10.1016/j.dsx.2006.11.006
M3 - Article
AN - SCOPUS:34247846308
VL - 1
SP - 37
EP - 42
JO - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
JF - Diabetes and Metabolic Syndrome: Clinical Research and Reviews
SN - 1871-4021
IS - 1
ER -